Depomed pays $47.5m for migraine drug Cambia in US
This article was originally published in Scrip
Executive Summary
That didn't take long: Depomed made good on its promise in October to use cash from the sale of its diabetes drug royalties to buy pain and neurology-focused assets. The company will pay Nautilus Neurosciences up to $52.5m for US rights to the migraine drug Cambia.